# Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

> **NCT03820596** · PHASE1,PHASE2 · COMPLETED · sponsor: **Huiqiang Huang** · enrollment: 40 (actual)

## Conditions studied

- Safety and Efficacy

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03820596
- **Lead sponsor:** Huiqiang Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-29
- **Primary completion:** 2020-05-20
- **Final completion:** 2021-11-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03820596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03820596, "Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03820596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*